BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 24732946)

  • 1. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.
    Wilson PM; Danenberg PV; Johnston PG; Lenz HJ; Ladner RD
    Nat Rev Clin Oncol; 2014 May; 11(5):282-98. PubMed ID: 24732946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
    Van Triest B; Pinedo HM; Giaccone G; Peters GJ
    Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
    Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
    Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer.
    Van Triest B; Peters GJ
    Oncology; 1999 Oct; 57(3):179-94. PubMed ID: 10545786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.
    Hernando-Cubero J; Matos-García I; Alonso-Orduña V; Capdevila J
    J Gastrointest Cancer; 2017 Jun; 48(2):135-147. PubMed ID: 28397102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
    Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
    J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
    Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase inhibitors.
    Danenberg PV; Malli H; Swenson S
    Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase: a critical target in cancer therapy?
    Rustum YM
    Front Biosci; 2004 Sep; 9():2467-73. PubMed ID: 15353299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A brief overview of a lung cancer biomarker: thymidylate synthase].
    Rouquette I; Mazieres J
    Rev Mal Respir; 2011 Jun; 28(6):773-7. PubMed ID: 21742238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase: a critical target for cancer chemotherapy.
    Rose MG; Farrell MP; Schmitz JC
    Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.
    van der Wilt CL; Peters GJ
    Pharm World Sci; 1994 Apr; 16(2):84-103. PubMed ID: 7518280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of pemetrexed in the treatment of colorectal cancer.
    Hochster H
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
    Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifolates in clinical development.
    Takimoto CH
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
    Brody JR; Hucl T; Gallmeier E; Winter JM; Kern SE; Murphy KM
    Cancer Res; 2006 Oct; 66(19):9369-73. PubMed ID: 17018589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of antifolate resistance.
    Assaraf YG
    Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
    Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
    Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance in colon cancer.
    Gorlick R; Bertino JR
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.